• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Thyroid and cardiovascular diseases.甲状腺疾病与心血管疾病。
Turk J Med Sci. 2024 Oct 1;54(7):1420-1427. doi: 10.55730/1300-0144.5927. eCollection 2024.
2
Effects of thyroid hormone on the cardiovascular system.甲状腺激素对心血管系统的影响。
Recent Prog Horm Res. 2004;59:31-50. doi: 10.1210/rp.59.1.31.
3
Thyroid status, cardiovascular risk, and mortality in older adults.老年人的甲状腺状态、心血管风险和死亡率
JAMA. 2006 Mar 1;295(9):1033-41. doi: 10.1001/jama.295.9.1033.
4
Thyroid gland dysfunction and its effect on the cardiovascular system: a comprehensive review of the literature.甲状腺功能障碍及其对心血管系统的影响:文献综述。
Endokrynol Pol. 2020;71(5):466-478. doi: 10.5603/EP.a2020.0052.
5
Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management.亚临床甲状腺功能亢进和减退的心血管风险:病理生理学与管理
J Cardiometab Syndr. 2007 Summer;2(3):198-206. doi: 10.1111/j.1559-4564.2007.06583.x.
6
FEATURES OF THYROID DYSFUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION.心房颤动患者甲状腺功能障碍的特征
Georgian Med News. 2024 Dec(357):95-98.
7
Thyroid disease and the cardiovascular system.甲状腺疾病与心血管系统。
Endocrinol Metab Clin North Am. 2014 Jun;43(2):517-28. doi: 10.1016/j.ecl.2014.02.005.
8
Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call?亚临床甲状腺功能障碍与心血管后果:令人警醒的警钟?
Trends Cardiovasc Med. 2020 Feb;30(2):57-69. doi: 10.1016/j.tcm.2019.02.011. Epub 2019 Mar 5.
9
Cardiovascular disease and thyroid function.心血管疾病与甲状腺功能
Front Horm Res. 2014;43:45-56. doi: 10.1159/000360558. Epub 2014 Jun 10.
10
Interplay between cardiovascular and thyroid dysfunctions: A review of clinical implications and management strategies.心脑血管与甲状腺功能紊乱的相互作用:临床意义及治疗策略综述。
Endocr Regul. 2022 Oct 20;56(4):311-328. doi: 10.2478/enr-2022-0033. Print 2022 Oct 1.

引用本文的文献

1
Association between the newly proposed dietary index for gut microbiota and thyroid function: NHANES 2007-2012.新提出的肠道微生物群饮食指数与甲状腺功能之间的关联:2007 - 2012年美国国家健康与营养检查调查(NHANES)
Front Nutr. 2025 Jun 26;12:1602787. doi: 10.3389/fnut.2025.1602787. eCollection 2025.

本文引用的文献

1
Epidemiology, prognosis, and challenges in the management of hyperthyroidism-related atrial fibrillation.甲状腺功能亢进相关心房颤动的流行病学、预后及管理挑战。
Eur Thyroid J. 2024 Apr 1;13(2). doi: 10.1530/ETJ-23-0254.
2
Hypothyroidism and Cardiovascular Disease: A Review.甲状腺功能减退症与心血管疾病:综述
Cureus. 2024 Jan 18;16(1):e52512. doi: 10.7759/cureus.52512. eCollection 2024 Jan.
3
Subclinical thyroid dysfunction and the risk of incident atrial fibrillation: A systematic review and meta-analysis.亚临床甲状腺功能障碍与房颤事件风险:系统评价和荟萃分析。
PLoS One. 2024 Jan 2;19(1):e0296413. doi: 10.1371/journal.pone.0296413. eCollection 2024.
4
Hyperthyroidism: A Review.甲状腺功能亢进症:综述。
JAMA. 2023 Oct 17;330(15):1472-1483. doi: 10.1001/jama.2023.19052.
5
Effect of thyroid hormone replacement treatment on cardiac diastolic function in adult patients with subclinical hypothyroidism: a meta-analysis.甲状腺激素替代治疗对亚临床甲状腺功能减退症成年患者心脏舒张功能的影响:一项荟萃分析。
Front Endocrinol (Lausanne). 2023 Sep 25;14:1263861. doi: 10.3389/fendo.2023.1263861. eCollection 2023.
6
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.《2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》2023年聚焦更新
Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
7
Thyrotoxic Cardiomyopathy: State of the Art.甲状腺毒症性心肌病:最新进展
touchREV Endocrinol. 2023 May;19(1):78-84. doi: 10.17925/EE.2023.19.1.78. Epub 2023 Feb 7.
8
Efficacy and safety of anticoagulation in thyrotoxic atrial fibrillation: a systematic review and meta-analysis.抗凝治疗在甲状腺毒症性心房颤动中的疗效与安全性:一项系统评价与荟萃分析。
Endocr Connect. 2022 May 23;11(5):e220166. doi: 10.1530/EC-22-0166.
9
Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes.甲状腺功能与糖尿病前期和 2 型糖尿病风险。
J Clin Endocrinol Metab. 2022 May 17;107(6):1789-1798. doi: 10.1210/clinem/dgac006.
10
Thyroid disorders and cardiovascular manifestations: an update.甲状腺疾病与心血管表现:最新进展。
Endocrine. 2022 Mar;75(3):672-683. doi: 10.1007/s12020-022-02982-4. Epub 2022 Jan 15.

甲状腺疾病与心血管疾病。

Thyroid and cardiovascular diseases.

作者信息

Tan Öksüz Sinem Başak, Şahin Mustafa

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye.

出版信息

Turk J Med Sci. 2024 Oct 1;54(7):1420-1427. doi: 10.55730/1300-0144.5927. eCollection 2024.

DOI:10.55730/1300-0144.5927
PMID:39735488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11673627/
Abstract

The thyroid gland is one of the major regulator organs of hemostasis in the human body, controlling the functioning of numerous systems. Thyroid hormones exert a modulating effect on the cardiovascular system in particular, ensuring optimal functioning within the normal range. Triiodothyronine (T3), as an active form of thyroid hormone, is mainly responsible for this effect via both genomic and nongenomic mechanisms. It has been reported that overt thyroid disorders are associated with a number of cardiovascular diseases and cardiac mortality. While hyperthyroidism appears to be related to atrial fibrillation and heart failure, the most pronounced cardiovascular complication of hypothyroidism seems to be atherosclerosis. Achieving euthyroidism is of great importance for restoring cardiovascular function. However, depending on the underlying health conditions, this may not be possible for all patients. Furthermore, there has been a growing focus on the role of subclinical thyroid dysfunctions and their impacts on the cardiovascular system in recent years. The pattern of cardiovascular abnormalities in subclinical thyroid disorders appears to parallel that of overt hypothyroidism, suggesting that even mild alterations in thyroid hormone levels may also have effects on the cardiovascular system. The management of subclinical thyroid disease remains controversial. Current evidence suggests that patient age and underlying cardiovascular diseases are major factors in clinical decision-making.

摘要

甲状腺是人体止血的主要调节器官之一,控制着众多系统的功能。甲状腺激素尤其对心血管系统发挥调节作用,确保其在正常范围内最佳运作。三碘甲状腺原氨酸(T3)作为甲状腺激素的一种活性形式,主要通过基因组和非基因组机制产生这种作用。据报道,明显的甲状腺疾病与多种心血管疾病及心脏死亡率相关。虽然甲状腺功能亢进似乎与心房颤动和心力衰竭有关,但甲状腺功能减退最显著的心血管并发症似乎是动脉粥样硬化。实现甲状腺功能正常对于恢复心血管功能至关重要。然而,根据潜在的健康状况,并非所有患者都能做到这一点。此外,近年来,亚临床甲状腺功能障碍的作用及其对心血管系统的影响受到越来越多的关注。亚临床甲状腺疾病中的心血管异常模式似乎与明显的甲状腺功能减退相似,这表明即使甲状腺激素水平的轻微变化也可能对心血管系统产生影响。亚临床甲状腺疾病的管理仍存在争议。目前的证据表明,患者年龄和潜在的心血管疾病是临床决策的主要因素。